ARMK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Aramark (ARMK) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support with multiple buy ratings and price target increases, solid revenue growth, and a positive technical setup. While there are some concerns about declining net income and EPS, the long-term growth potential and recent large contract wins outweigh these negatives.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 61.418, and moving averages are converging, suggesting a potential breakout. The stock is trading above its pivot level of 40.278, with resistance at 42.108 and support at 38.449.
Revenue growth of 6.14% YoY in Q1
Large contract win with RWJ Barnabas Health starting in June 2026.
Net income decreased by 8.95% YoY, and EPS dropped by 7.69% YoY. Gross margin declined by 4.91%. No recent significant hedge fund or insider activity.
In Q1 2026, revenue increased by 6.14% YoY to $4.83 billion, but net income dropped by 8.95% YoY to $96.16 million. EPS fell by 7.69% to 0.36, and gross margin decreased by 4.91% to 6.01%.
Analysts are highly bullish on Aramark, with multiple buy ratings and price target increases from firms like Truist, BofA, Citi, and JPMorgan. Price targets now range from $45 to $51, with a consensus around $50.
